Skip to content
    DOC
    Earnings call· Mar 2026(Q1 FY26)

    HEALTHPEAK PROPERTIES Q1 FY26 earnings call DOC

    May 6, 2026 Source

    Executive summary

    Healthpeak Q1 FY26 — Strong Operational Performance and Strategic Capital Initiatives

    Healthpeak delivered a strong first quarter, marked by strategic capital initiatives and robust operational performance across its segments. The successful IPO of Janus Living and a joint venture recap with Blackstone highlight the company's ability to unlock value and attract institutional capital. While the lab business shows positive momentum with increasing occupancy and a broad leasing pipeline, the company remains disciplined in capital allocation, focusing on accretive opportunities and managing refinancing headwinds.

    Highlights

    5

    • Gateway campus leasing momentum with 62,000 square feet of signed leases and letters of intent, plus 113,000 square feet of active proposals and tours.

    • Successful IPO of senior housing business (Janus Living) with $240 million of current year FFO now valued at a multiple roughly 20 turns higher than Healthpeak.

    • Outpatient Medical achieved 5.4% cash re-leasing spreads on renewals in Q1, with an average of 5.8% since the merger.

    • Stock buyback of $100 million in April at an implied FFO yield of over 10%, which was accretive to earnings.

    • Lab total occupancy increased sequentially to 77.7% and is expected to grow by at least 100 basis points versus year-end 2025.

    Concerns

    3

    • Refinancing $650 million of senior notes at 3.5% in June will create an additional headwind in the second half of the year.

    • Temporary earnings drag from cash proceeds on the balance sheet post-IPO and incremental public company costs for Janus Living.

    • Boston lab market still faces a supply-demand imbalance, though specific portfolio performance is strong.

    Guidance & targets

    6
    CategoryTargetConfidence
    FFO as adjusted per share
    $1.71 to $1.75
    high materiality
    High
    Janus Living IPO earnings impact
    earnings neutral
    high materiality
    High
    Lab total occupancy growth
    at least 100 basis points
    medium materiality
    High
    Alewife project entitlements
    completion
    low materiality
    Medium
    Alewife residential building groundbreaking
    Q1 2027 or 12-18 months after entitlements
    low materiality
    Medium
    Additional capital recycling transactions
    $700 million or more
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Outpatient Medical
    Strong fundamentals continue, with successful leasing activities and low leasing costs driving strong cash returns. The Baylor Cancer Center campus saw 10-year lease renewals across 458,000 square feet with minimal leasing costs.
    Leases executed: 1.1 million square feetCash re-leasing spreads on renewals: 5.4%Tenant retention: 79%Total occupancy: 91%Average annual escalators: 3%Leasing costs: 10% of annual rentsLeasing pipeline executed since April: 318,000 square feetLeasing pipeline under LOI: 700,000 square feet
    		————
    Lab
    Leasing momentum is building, with a broad-based pipeline. South San Francisco shows the strongest active demand. Expect net absorption and occupancy growth by year-end.
    Leases executed: 141,000 square feetNew leasing (of executed leases): 92%Leasing under LOI: 355,000 square feetNew leasing (of LOI): 80%Vacant space (of LOI): 75%Total occupancy: 77.7% (up sequentially)Expirations in 2026: 400,000 square feetCommencements in 2026: over 500,000 square feetKnown move-outs mid-year: 50,000 square feet (2 tenants)
    		————
    Senior Housing (Janus Living)
    Delivered phenomenal results in Q1. The IPO strengthens investment management capabilities and expands reach to investors. Healthpeak's ownership stake ensures benefit from Janus Living's accretive acquisitions.
    Adjusted EBITDA growth: 42%Healthpeak ownership: 81.6% of outstanding sharesMarket value of Healthpeak's ownership: roughly $5.7 billionEntry fees: all-time high for the first quarter
    		—35%——

    Operational metrics

    10
    Net debt to EBITDA
    5.4x
    Q1 FY26
    Stock repurchased
    $100 million
    April 2026

    The repurchase was accretive to earnings.

    Dividends paid
    over $200 million
    Q1 FY26

    Equates to an outrageously high 7.5% annualized dividend yield with a solid payout ratio.

    Outpatient Medical average same-store NOI growth
    3.5%30% higher than previous 5-year average
    last 5 years

    Driven by successfully getting 3% escalators on new leases and renewals for about 5 years.

    Capital invested
    $1 billion
    Q1 FY26

    Part of the $1 billion acquisitions target.

    Capital recycling proceeds received
    $270 million
    Q1 FY26

    Progress towards the $1 billion capital recycling target.

    Senior notes to refinance
    $650 million3.5% coupon
    June 2026

    Refinancing these notes will be an additional headwind in the second half of the year.

    Lab cash re-leasing spreads
    5%
    last 12 months

    Achieved on average.

    Lab cash re-leasing spreads
    3.5%
    Q1 FY26

    Achieved in the current quarter.

    Lab average rent per square foot
    $60
    current

    Portfolio average rent.

    Industry KPIs

    1
    MetricValueDetails
    Investment volume and sourcing mix$714 millionUSD

    Orderbook & backlog

    1
    Lab leasing pipeline2 million square feetQ1 FY26

    Represents opportunity in the lab portfolio to drive earnings growth.

    Deals & partnerships

    3
    Janus LivingInitial Public Offering (IPO) of senior housing business

    Healthpeak retains 81.6% ownership of Janus Living, representing roughly a $5.7 billion market value. The timing of the IPO was intentional to capture multiple arbitrage for shareholders.

    BlackstoneRecapitalization of a fully occupied outpatient portfolio$170 million

    Healthpeak co-invested as a minority share (20% interest). The partnership leverages Healthpeak's platform and relationships.

    HinesMultifamily development at Alewife mixed-use project

    Hines will be leading the multifamily opportunity, which constitutes half of the 5 million square feet mixed-use project.

    Capital programs

    2
    Gateway Campus Acquisitionclosed
    Start: late December 2025 / early January 2026

    Acquired for a small fraction of replacement cost, already driving leasing momentum. Expected to contribute to earnings in 2027 and beyond.

    Alewife Mixed-Use Projectunderway

    Benefit: 5 million square feet (total), half multifamily residential

    Received preliminary planning board approval. Hines partnered on the multifamily opportunity. Residential groundbreaking expected in 2027 or 12-18 months after entitlements.

    Risks & headwinds

    4
    Refinancing of senior notesJune 2026 (H2 FY26)

    $650 million of senior notes at 3.5%

    Mitigation: Not explicitly stated, but implies active balance sheet management.

    Temporary earnings drag from IPO proceedsFY26

    Impact on 2026 earnings

    Mitigation: Expected to be offset by senior housing portfolio outperformance and deployment of $750 million of cash into acquisitions by year-end.

    Incremental public company costsFY26

    Impact on 2026 earnings

    Mitigation: Expected to be offset by senior housing portfolio outperformance and deployment of $750 million of cash into acquisitions by year-end.

    Lab market supply-demand imbalance

    Boston market

    Mitigation: Focus on competitive portfolio, specific submarkets (West Cambridge), and capturing available demand with a strong team.

    What to watch in Q2 FY26

    5

    Lab total occupancy growth

    next quarter / year-end FY26
    Current77.7%
    Targetprogress towards at least 100 bps increase vs YE25

    Why it matters

    Lab occupancy is a key driver for future earnings growth and indicates the health of the life science market recovery.

    We ended the quarter with total occupancy up to 77.7%, and for the balance of the year, we expect to continue to capture occupancy from the benefit of new leasing commencements, which will support occupancy growth of at least 100 basis points versus year-end 2025.

    Q&A highlights

    7

    How has the positive outlook for the life science pipeline influenced the timing and strategy for opportunistic life science investments?

    The company remains disciplined, prioritizing existing capital recycling targets and buybacks. While opportunities exist, especially with distressed private buyers and lenders, Healthpeak's threshold for new investments is high, focusing on core markets, specific buildings, and careful valuation.

    “We're looking at some other things in our core markets, but our threshold is pretty high for using capital. Obviously, we did the buybacks in April. That was a very accretive use of capital.”

    asked by Farrell Granath · answered by Scott Brinker

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Capital Initiatives and Value Creation

    Healthpeak executed several strategic capital initiatives in Q1 FY26, including the successful IPO of its senior housing business, Janus Living, which now values its FFO at a significantly higher multiple than Healthpeak. The company also completed a joint venture recapitalization with Blackstone on a fully occupied outpatient portfolio, generating $170 million in proceeds at a 6.1% cash cap rate. These moves demonstrate Healthpeak's ability to unlock value and attract institutional capital, with the Janus Living IPO expected to be earnings neutral in 2026 and accretive by approximately $0.04 per share on a run rate basis in 2027 and beyond.

    02

    Outpatient Medical Platform Strength

    The Outpatient Medical segment continues to exhibit strong fundamentals, validating the company's merger thesis from three years ago. The segment achieved 5.4% cash re-leasing spreads on renewals in Q1, with an average of 5.8% since the merger, and maintained 3% average annual escalators. Low leasing costs, at just 10% of annual rents, contribute to strong net effective rents and superior cash flow. The segment's active leasing pipeline includes 318,000 square feet executed since April and approximately 700,000 square feet under LOI, indicating continued momentum.

    03

    Life Science Market Recovery and Portfolio Performance

    The Life Science segment is showing positive signs of recovery, with M&A activity, biopharma stock prices, and capital raising all trending positively. April marked the most active month for biotech equity issuance since early 2021. Healthpeak's total occupancy in Life Science increased sequentially to 77.7% and is projected to increase by at least 100 basis points versus year-end 2025. The leasing pipeline is broad-based, encompassing venture-backed biotech to large-cap pharma, with traditional wet lab space accounting for the majority of demand.

    04

    Disciplined Capital Allocation and Balance Sheet Management

    Healthpeak repurchased $100 million of its stock in April at an implied FFO yield exceeding 10%, contributing to an increase in its FFO guidance. The company also paid over $200 million in dividends in Q1, representing a 7.5% annualized yield. In Q1, Healthpeak invested $714 million in senior housing acquisitions prior to the Janus Living IPO and repaid $103 million of secured mortgages. A new $400 million senior unsecured delayed draw term loan was closed in March, remaining undrawn, providing future liquidity.

    05

    Gateway Campus and Alewife Project Updates

    The Gateway campus acquisition in South San Francisco, completed in early January, is performing ahead of underwriting expectations, with significant leasing momentum already observed. The Alewife mixed-use project in Boston received preliminary planning board approval, a step towards completing entitlements by Q4 2026. This project, which includes a partnership with Hines for multifamily development, could see residential groundbreaking in 2027, showcasing long-term development potential.

    AI-generated summary of the company’s earnings call. Not investment advice.